Ulrica Wilderäng

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Community Dwelling

Ejection Fraction

Top Venues

Circulation. Heart failure

This page only lists publications with an associated author ORCID identifier.

Publications

John Joseph Valentine McMurray, Kieran F Docherty, Rudolf A de Boer, Ann Hammarstedt, Dalane W Kitzman, Mikhail Naum Kosiborod, Anna Maria Langkilde, Barry Reicher, Michele Senni, Sanjiv J Shah, Ulrica Wilderäng, Subodh Verma, Scott D Solomon
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation (2023)
Alexander Peikert, Felipe A Martinez, Muthiah Vaduganathan, Brian Lee Claggett, Ian J Kulac, Akshay S Desai, Pardeep S Jhund, Rudolf A de Boer, David L DeMets, Adrian F Hernandez, Catherine M Viscoli, Mikhail Naum Kosiborod, Carolyn Su Ping Lam, Sanjiv J Shah, Tsvetana Katova, Béla Merkely, Orly Vardeny, Ulrica Wilderäng, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde, John Joseph Valentine McMurray, Scott D Solomon
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation. Heart failure 15 (10) (2022)
Jawad H Butt, Pardeep S Jhund, Jan Belohlávek, Rudolf A de Boer, Chern-En Chiang, Akshay S Desai, Jarosław Drożdż, Adrian F Hernandez, Catherine M Viscoli, Tzvetana Katova, Masafumi Kitakaze, Mikhail Naum Kosiborod, Carolyn Su Ping Lam, Anna Maria Langkilde, Daniel Lindholm, Erasmus Bachus, Felipe A Martinez, Bela Merkely, Magnus Petersson, Jose F Kerr Saraiva, Sanjiv J Shah, Muthiah Vaduganathan, Orly Vardeny, Ulrica Wilderäng, Brian Lee Claggett, Scott D Solomon, John Joseph Valentine McMurray
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 146 (16) (2022)